{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:15:03Z","timestamp":1793218503063,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Androgen deprivation therapy (ADT) is the backbone of systemic therapy for men with prostate cancer (PC); almost one-half of patients receive treatment during their disease course. However, a range of cognitive and other central nervous system (CNS) changes have been associated with ADT. In this review, we discuss extant data describing these complications and the mechanisms through which medications used to deliver ADT may affect them.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a MEDLINE search for appropriate papers published between January 2000 and December 2018. Relevant papers were selected and reviewed; additional publications were identified by manually assessing references from included papers, and recent congress abstracts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of ~230 search outputs, 33 were selected for inclusion. Some studies suggested a clear association between ADT and CNS effects in men with PC, whereas others did not. Accurate assessment is limited by test instrument variability, inadequate sample sizes, short follow-up duration, and limited prospective longitudinal studies. The approved second-generation androgen receptor (AR) inhibitors enzalutamide and apalutamide were associated with some CNS-related adverse events (AEs) in clinical studies, including fatigue (which can interfere with cognitive function). The androgen synthesis inhibitor abiraterone acetate was associated with a low CNS AE profile when compared with enzalutamide. The AR antagonist darolutamide demonstrated a comparable incidence of cognitive disorder in clinical trials to that of ADT alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adequately caring for men receiving ADT requires an understanding of the symptoms, incidence and magnitude of cognitive effects, and a feasible approach to cognitive assessment and management in clinical settings. Some CNS effects could relate to blood\u2013brain barrier penetration and direct AR inhibitor activity; drug safety profiles may differ by the degree of blood\u2013brain barrier penetration of particular agents. Ongoing clinical trials seek to define the CNS tolerability of newer AR pathway-targeted therapy options more clearly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-019-0195-5","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:02:42Z","timestamp":1576504962000},"page":"207-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["A review of prostate cancer treatment impact on the CNS and cognitive function"],"prefix":"10.1038","volume":"23","author":[{"given":"Charles","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Wefel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"195_CR1","unstructured":"Global Cancer Observatory. Cancer today data table. 2018. http:\/\/gco.iarc.fr\/today\/home Accessed 11 June 2019."},{"key":"195_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"195_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5489\/cuaj.2526","volume":"9","author":"F Saad","year":"2015","unstructured":"Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015;9:90\u20136.","journal-title":"Can Urol Assoc J"},{"issue":"Suppl 5","key":"195_CR4","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","volume":"26","author":"C Parker","year":"2015","unstructured":"Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69\u201377.","journal-title":"Ann Oncol."},{"key":"195_CR5","unstructured":"National Comprehensive Cancer Network. NCCN: National Comprehensive Cancer Network clinical practice guidelines in oncology: prostate cancer. Version 1. 2017. www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site. Accessed 11 June 2019."},{"key":"195_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618\u201329.","journal-title":"Eur Urol"},{"key":"195_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.juro.2014.10.104","volume":"193","author":"MS Cookson","year":"2015","unstructured":"Cookson MS, Lowrance WT, Murad MH, Kibel AS. American Urological Association. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015;193:491\u20139.","journal-title":"J Urol"},{"key":"195_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0759-3","volume":"33","author":"L Graham","year":"2016","unstructured":"Graham L, Schweizer MT. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Med Oncol. 2016;33:44.","journal-title":"Med Oncol."},{"key":"195_CR9","unstructured":"Food and Drug Administration. Prescribing information: ZYTIGA. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202379s027s028lbl.pdf. Accessed 11 June 2019."},{"key":"195_CR10","unstructured":"European Medicines Agency. Summary of product characteristics: ZYTIGA. 2019. https:\/\/www.ema.europa.eu\/documents\/product-information\/zytiga-epar-product-information_en.pdf. Accessed 16 October 2018."},{"key":"195_CR11","unstructured":"Pharmaceuticals and Medical Devices Agency Japan. New drugs approved in financial year 2014. 2015. https:\/\/www.pmda.go.jp\/files\/000229076.pdf. Accessed 11 June 2019."},{"key":"195_CR12","unstructured":"Astellas Pharma US Inc. Xtandi (enzalutamide) US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203415s014lbl.pdf. Accessed 11 June 2019."},{"key":"195_CR13","unstructured":"European Medicines Agency. Summary of product characteristics: XTANDI. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf. Accessed 11 June 2019."},{"key":"195_CR14","unstructured":"Pharmaceuticals and Medical Devices Agency Japan. New drugs approved in financial year 2013. 2014. https:\/\/www.pmda.go.jp\/files\/000153463.pdf. Accessed 11 June 2019."},{"key":"195_CR15","unstructured":"Food and Drug Administration. Prescribing Information: ERLEADA. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210951s000lbl.pdf. Accessed 11 June 2019."},{"key":"195_CR16","unstructured":"European Medicines Agency. Summary of product characteristics: ERLEADA. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erleada-epar-product-information_en.pdf. Accessed 11 June 2019."},{"key":"195_CR17","unstructured":"Pharmaceuticals and Medical Devices Agency Japan. New drugs approved in financial year 2018. 2019. https:\/\/www.pmda.go.jp\/files\/000229856.pdf. Accessed 11 June 2019."},{"key":"195_CR18","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Nubeqa (darolutamide) US prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf. Accessed 31 July 2019."},{"key":"195_CR19","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00520-014-2285-1","volume":"22","author":"HL McGinty","year":"2014","unstructured":"McGinty HL, Phillips KM, Jim HS, Cessna JM, Asvat Y, Cases MG, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22:2271\u201380.","journal-title":"Support Care Cancer"},{"key":"195_CR20","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","volume":"33","author":"BD Gonzalez","year":"2015","unstructured":"Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33:2021\u201327.","journal-title":"J Clin Oncol"},{"key":"195_CR21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.maturitas.2011.05.012","volume":"69","author":"J Holland","year":"2011","unstructured":"Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas. 2011;69:322\u201337.","journal-title":"Maturitas."},{"key":"195_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2015.01.026","volume":"68","author":"CS Higano","year":"2015","unstructured":"Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, et al. Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur Urol. 2015;68:795\u2013801.","journal-title":"Eur Urol"},{"key":"195_CR23","first-page":"143","volume":"10","author":"D Pilon","year":"2017","unstructured":"Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA. Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. Am Health Drug Benefits. 2017;10:143\u201353.","journal-title":"Am Health Drug Benefits"},{"key":"195_CR24","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408\u201318.","journal-title":"N Engl J Med"},{"key":"195_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","volume":"19","author":"RJ Auchus","year":"2014","unstructured":"Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist. 2014;19:1231\u201340.","journal-title":"Oncologist."},{"key":"195_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1517\/14656566.2015.1016911","volume":"16","author":"JN Graff","year":"2015","unstructured":"Graff JN, Gordon MJ, Beer TM. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. Expert Opin Pharmacother. 2015;16:749\u201354.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 15","key":"195_CR27","doi-asserted-by":"publisher","first-page":"abstr 5059","DOI":"10.1200\/JCO.2016.34.15_suppl.5059","volume":"34","author":"S Parimi","year":"2016","unstructured":"Parimi S, Eigl BJ, Sunderland K, Zulfiqar M, Finch DL, Oja CD, et al. Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2016;34 Suppl 15:abstr 5059.","journal-title":"J Clin Oncol"},{"key":"195_CR28","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465\u201374.","journal-title":"N Engl J Med"},{"key":"195_CR29","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.juro.2006.07.151","volume":"176","author":"F Joly","year":"2006","unstructured":"Joly F, Alibhai SM, Galica J, Park A, Yi QL, Wagner L, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176:2443\u201347.","journal-title":"J Urol"},{"key":"195_CR30","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1200\/JCO.2010.30.8742","volume":"28","author":"SM Alibhai","year":"2010","unstructured":"Alibhai SM, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, et al. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28:5030\u201337.","journal-title":"J Clin Oncol"},{"key":"195_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-009-0625-3","volume":"18","author":"HS Jim","year":"2010","unstructured":"Jim HS, Small BJ, Patterson S, Salup R, Jacobsen PB. Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. Support Care Cancer. 2010;18:21\u20137.","journal-title":"Support Care Cancer"},{"key":"195_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1200\/JCO.2015.63.6266","volume":"34","author":"KT Nead","year":"2016","unstructured":"Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, et al. Androgen deprivation therapy and future Alzheimer's disease risk. J Clin Oncol. 2016;34:566\u201371.","journal-title":"J Clin Oncol"},{"key":"195_CR33","first-page":"3681","volume":"84","author":"E Barrett-Connor","year":"1999","unstructured":"Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab. 1999;84:3681\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"195_CR34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1530\/eje.1.02306","volume":"155","author":"O Beauchet","year":"2006","unstructured":"Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol. 2006;155:773\u201381.","journal-title":"Eur J Endocrinol"},{"key":"195_CR35","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1073\/pnas.94.14.7537","volume":"94","author":"JE Morley","year":"1997","unstructured":"Morley JE, Kaiser F, Raum WJ, Perry HM 3rd, Flood JF, Jensen J, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA. 1997;94:7537\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"195_CR36","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1212\/01.WNL.0000153072.54068.E3","volume":"64","author":"M Muller","year":"2005","unstructured":"Muller M, Aleman A, Grobbee DE, de Haan EH, van der Schouw YT. Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level? Neurology. 2005;64:866\u201371.","journal-title":"Neurology."},{"key":"195_CR37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1046\/j.1532-5415.2002.50166.x","volume":"50","author":"K Yaffe","year":"2002","unstructured":"Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc. 2002;50:707\u201312.","journal-title":"J Am Geriatr Soc"},{"key":"195_CR38","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.neuroscience.2005.09.007","volume":"138","author":"JS Janowsky","year":"2006","unstructured":"Janowsky JS. The role of androgens in cognition and brain aging in men. Neuroscience. 2006;138:1015\u201320.","journal-title":"Neuroscience."},{"key":"195_CR39","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0306-9877(02)00447-4","volume":"60","author":"RS Tan","year":"2003","unstructured":"Tan RS, Pu SJ, Culberson JW. Role of androgens in mild cognitive impairment and possible interventions during andropause. Med Hypotheses. 2003;60:448\u201352.","journal-title":"Med Hypotheses"},{"key":"195_CR40","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/cncr.23658","volume":"113","author":"CJ Nelson","year":"2008","unstructured":"Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113:1097\u2013106.","journal-title":"Cancer."},{"key":"195_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.juro.2018.02.073","volume":"200","author":"S Marzouk","year":"2018","unstructured":"Marzouk S, Naglie G, Tomlinson G, Duff Canning S, Breunis H, Timilshina N, et al. Impact of androgen deprivation therapy on self-reported cognitive function in men with prostate cancer. J Urol. 2018;200:327\u201334.","journal-title":"J Urol"},{"key":"195_CR42","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ctrv.2012.05.002","volume":"38","author":"AD Hutchinson","year":"2012","unstructured":"Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske J, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38:926\u201334.","journal-title":"Cancer Treat Rev"},{"key":"195_CR43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","volume":"12","author":"JS Wefel","year":"2011","unstructured":"Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703\u20138.","journal-title":"Lancet Oncol."},{"key":"195_CR44","first-page":"465","volume":"166","author":"VB Shahinian","year":"2006","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the \"androgen deprivation syndrome\" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166:465\u201371.","journal-title":"Arch Intern Med"},{"key":"195_CR45","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.juro.2017.11.136","volume":"199","author":"M Sun","year":"2018","unstructured":"Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018;199:1417\u201325.","journal-title":"J Urol."},{"key":"195_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jamaoncol.2016.3662","volume":"3","author":"KT Nead","year":"2017","unstructured":"Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3:49\u201355.","journal-title":"JAMA Oncol."},{"key":"195_CR47","doi-asserted-by":"crossref","unstructured":"Tae BS, Jeon BJ, Shin SH, Choi H, Bae JH, Park JY. Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: a nationwide population-based study using the national health insurance service database. Cancer Res Treat. 2019;51:593\u2013602.","DOI":"10.4143\/crt.2018.119"},{"key":"195_CR48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/aja.2011.107","volume":"14","author":"RJ Jamadar","year":"2012","unstructured":"Jamadar RJ, Winters MJ, Maki PM. Cognitive changes associated with ADT: a review of the literature. Asian J Androl. 2012;14:232\u201338.","journal-title":"Asian J Androl"},{"key":"195_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.socscimed.2016.03.016","volume":"156","author":"LM Wu","year":"2016","unstructured":"Wu LM, Tanenbaum ML, Dijkers MP, Amidi A, Hall SJ, Penedo FJ, et al. Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: a mixed methods study. Soc Sci Med. 2016;156:80\u201389.","journal-title":"Soc Sci Med"},{"key":"195_CR50","doi-asserted-by":"publisher","first-page":"T119","DOI":"10.1530\/ERC-13-0467","volume":"21","author":"CA Allan","year":"2014","unstructured":"Allan CA, Collins VR, Frydenberg M, McLachlan RI, Matthiesson KL. Androgen deprivation therapy complications. Endocr Relat Cancer. 2014;21:T119\u201329.","journal-title":"Endocr Relat Cancer"},{"key":"195_CR51","first-page":"63","volume":"5","author":"H Ahmadi","year":"2014","unstructured":"Ahmadi H, Daneshmand S. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Relat Outcome Meas. 2014;5:63\u201370.","journal-title":"Patient Relat Outcome Meas"},{"key":"195_CR52","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.juro.2018.07.090","volume":"200","author":"WT Lowrance","year":"2018","unstructured":"Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS. Castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol. 2018;200:1264\u201372.","journal-title":"J Urol."},{"key":"195_CR53","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72:1494\u2013503.","journal-title":"Cancer Res."},{"key":"195_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/srep12007","volume":"5","author":"AM Moilanen","year":"2015","unstructured":"Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.","journal-title":"Sci Rep."},{"issue":"Suppl","key":"195_CR55","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1200\/JCO.2018.36.6_suppl.345","volume":"36","author":"C Zurth","year":"2018","unstructured":"Zurth C, Sandmann S, Trummel D, Seidel D, Gieschen H. Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography. J Clin Oncol. 2018;36 Suppl 6:345.","journal-title":"J Clin Oncol"},{"key":"195_CR56","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/pros.21263","volume":"71","author":"WR Foster","year":"2011","unstructured":"Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2011;71:480\u20138.","journal-title":"Prostate."},{"issue":"Suppl 3","key":"195_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.1528-1157.2001.042suppl.3008.x","volume":"42","author":"DM Treiman","year":"2001","unstructured":"Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42 Suppl 3:8\u201312.","journal-title":"Epilepsia."},{"key":"195_CR58","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"195_CR59","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437\u201346.","journal-title":"Lancet."},{"key":"195_CR60","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14656566.2017.1329820","volume":"18","author":"ND Shore","year":"2017","unstructured":"Shore ND. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother. 2017;18:945\u201352.","journal-title":"Expert Opin Pharmacother"},{"key":"195_CR61","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","volume":"15","author":"B Tombal","year":"2014","unstructured":"Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014;15:592\u2013600.","journal-title":"Lancet Oncol"},{"key":"195_CR62","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"195_CR63","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755\u20136.","journal-title":"N Engl J Med"},{"key":"195_CR64","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"195_CR65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17:153\u201363.","journal-title":"Lancet Oncol."},{"issue":"Suppl 5","key":"195_CR66","first-page":"v269","volume":"28","author":"MS Iznaola","year":"2017","unstructured":"Iznaola MS, Parra R, Angela G, Casariego J, MuNoz Del Toro J, Robinson P. Neuropsychiatric adverse events of enzalutamide and abiraterone acetate plus prednison treatment: contrasting a meta-analysis of randomized clinical trials with real world reporting from EUDRA (abstract 831P). Ann Oncol. 2017;28 Suppl 5:v269\u2013v94.","journal-title":"Ann Oncol"},{"issue":"Suppl 6S","key":"195_CR67","doi-asserted-by":"publisher","first-page":"abstr 296","DOI":"10.1200\/JCO.2018.36.6_suppl.296","volume":"36","author":"ND Shore","year":"2018","unstructured":"Shore ND, Saltzstein DR, Sieber PR, Mehlhaff B, Gervasi L, Phillips J, et al. Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): results. J Clin Oncol 2018;36 Suppl 6S:abstr 296.","journal-title":"J Clin Oncol"},{"key":"195_CR68","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","volume":"24","author":"D Cella","year":"2002","unstructured":"Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag. 2002;24:547\u201361.","journal-title":"J Pain Symptom Manag"},{"key":"195_CR69","doi-asserted-by":"publisher","first-page":"e000397","DOI":"10.1136\/esmoopen-2018-000397","volume":"3","author":"A Thiery-Vuillemin","year":"2018","unstructured":"Thiery-Vuillemin A, Poulsen MH, Lagneau E, Ploussard G, Birtle A, Dourthe LM, et al. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study. ESMO Open. 2018;3:e000397.","journal-title":"ESMO Open"},{"key":"195_CR70","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/jamaoncol.2017.3361","volume":"4","author":"S Slovin","year":"2018","unstructured":"Slovin S, Clark W, Carles J, Krivoshik A, Park JW, Wang F, et al. Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study. JAMA Oncol. 2018;4:702\u201306.","journal-title":"JAMA Oncol"},{"key":"195_CR71","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40261-017-0578-0","volume":"37","author":"C Dharmani","year":"2017","unstructured":"Dharmani C, Bonafede M, Krivoshik A. Risk factors for and incidence of seizures in metastatic castration-resistant prostate cancer: a real-world retrospective cohort study. Clin Drug Investig. 2017;37:1183\u201390.","journal-title":"Clin Drug Investig"},{"key":"195_CR72","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/annonc\/mdv542","volume":"27","author":"JN Graff","year":"2016","unstructured":"Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27:286\u201394.","journal-title":"Ann Oncol."},{"key":"195_CR73","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"195_CR74","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"195_CR75","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.clgc.2016.06.010","volume":"15","author":"H Miyake","year":"2017","unstructured":"Miyake H, Hara T, Terakawa T, Ozono S, Fujisawa M. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15:313\u201319.","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 6S","key":"195_CR76","doi-asserted-by":"publisher","first-page":"abstr 217","DOI":"10.1200\/JCO.2018.36.6_suppl.217","volume":"36","author":"MPM Perez","year":"2018","unstructured":"Perez MPM, Iznaola MS, Garcia A, del Toro JM, Casariego J, Robinson P, et al. Neuropsychiatric adverse events of enzalutamide and abiraterone acetate: metaanalysis of randomized clinical trials with real world reporting patterns from EudraVigilance. J Clin Oncol. 2018;36 Suppl 6S:abstr 217.","journal-title":"J Clin Oncol."},{"issue":"Suppl 6S","key":"195_CR77","doi-asserted-by":"publisher","first-page":"abstr 196","DOI":"10.1200\/JCO.2018.36.6_suppl.196","volume":"36","author":"G Gotto","year":"2018","unstructured":"Gotto G, Fradet V, Drachenberg D, Sabbagh R, Rendon RA, Shayegan B, et al. Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P). J Clin Oncol. 2018;36 Suppl 6S:abstr 196.","journal-title":"J Clin Oncol"},{"key":"195_CR78","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","volume":"70","author":"MR Smith","year":"2016","unstructured":"Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70:963\u201370.","journal-title":"Eur Urol."},{"issue":"Suppl 15","key":"195_CR79","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1200\/JCO.2019.37.15_suppl.5025","volume":"37","author":"Y Pollock","year":"2019","unstructured":"Pollock Y, Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, et al. Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). J Clin Oncol. 2019;37 Suppl 15:5025.","journal-title":"J Clin Oncol."},{"key":"195_CR80","unstructured":"ClinicalTrials.gov. NCT01946204: a study of apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer (SPARTAN). 2019. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01946204. Accessed 11 June 2019."},{"key":"195_CR81","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00120-017-0329-0","volume":"56","author":"H Rexer","year":"2017","unstructured":"Rexer H, Graefen M. Phase III study for local or locally advanced prostate cancer: randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS)\u2014study AP 90\/15 of the AUO. Urol A. 2017;56:243\u201344.","journal-title":"Urol A"},{"key":"195_CR82","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15:975\u201385.","journal-title":"Lancet Oncol."},{"key":"195_CR83","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2015.09.046","volume":"69","author":"C Massard","year":"2016","unstructured":"Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016;69:834\u201340.","journal-title":"Eur Urol."},{"key":"195_CR84","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.euf.2016.01.005","volume":"2","author":"M Reza","year":"2016","unstructured":"Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M, et al. Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. Eur Urol. Focus 2016;2:547\u201352.","journal-title":"Eur Urol. Focus"},{"issue":"Suppl 4","key":"195_CR85","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1200\/jco.2014.32.4_suppl.275","volume":"32","author":"ND Shore","year":"2014","unstructured":"Shore ND, Bono P, Massard C, Snapir A, Sarapohja T, Fizazi K. ODM-201 and the CNS: a clinical perspective. J Clin Oncol. 2014;32 Suppl 4:275\u201375.","journal-title":"J Clin Oncol."},{"key":"195_CR86","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235\u201346.","journal-title":"N Engl J Med"},{"issue":"Suppl 6S","key":"195_CR87","doi-asserted-by":"publisher","first-page":"abstr TPS383","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS383","volume":"36","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Hussain M, Sternberg CN, Fizazi K, Yamada KS, et al. ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol. 2018;36 Suppl 6S:abstr TPS383.","journal-title":"J Clin Oncol"},{"key":"195_CR88","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1017\/S1478951507000442","volume":"5","author":"CJ Nelson","year":"2007","unstructured":"Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5:273\u201380.","journal-title":"Palliat Support Care"},{"key":"195_CR89","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.urolonc.2012.07.003","volume":"31","author":"LM Wu","year":"2013","unstructured":"Wu LM, Diefenbach MA, Gordon WA, Cantor JB, Cherrier MM. Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study. Urol Oncol. 2013;31:1533\u20138.","journal-title":"Urol Oncol."},{"key":"195_CR90","unstructured":"National Comprehensive Cancer Network. NCCN: National Comprehensive Cancer Network clinical practice guidelines in oncology: cognitive function. Plymouth, PA: National Comprehensive Cancer Network; 2018."},{"key":"195_CR91","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s13670-016-0182-9","volume":"5","author":"A Magnuson","year":"2016","unstructured":"Magnuson A, Mohile S, Janelsins M. Cognition and cognitive impairment in older adults with cancer. Curr Geriatr Rep. 2016;5:213\u201319.","journal-title":"Curr Geriatr Rep"},{"key":"195_CR92","unstructured":"National Comprehensive Cancer Network. NCCN: National Comprehensive Cancer Network Clinical practice guidelines in oncology: prostate cancer. Version 1. 2017. www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site. Accessed 23 November 2017."},{"key":"195_CR93","unstructured":"National Center for Biotechnology Information. PubChem compound database: enzalutamide. 2019. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/15951529. Accessed 11 June 2019."},{"key":"195_CR94","unstructured":"National Center for Biotechnology Information. PubChem compound database: apalutamide. 2019. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/24872560. Accessed 11 June 2019."}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0195-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:34:32Z","timestamp":1684604072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-019-0195-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["195"],"URL":"https:\/\/doi.org\/10.1038\/s41391-019-0195-5","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"8 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CR has received honoraria from Janssen, Bayer and Sanofi Aventis. JSW has acted as a consultant for: Angiochem, Juno, Novocure, Vanquish Oncology and Magnolia Tejas, and has been an Advisory Board member for: AbbVie, Bayer, Blueprint Medicines, and Magnolia Neurosciences. AKM has received honoraria from AstraZeneca, Astellas, Bayer, Janssen, Sanofi, Genentech, and Seattle Genetics, and has received funding for an investigator-initiated study from Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}